Important Progress In Treatment Of Early And Late Stage Breast Cancer With Herceptin, Avastin And T-

< BACK TO HEALTH starstarstarstarstar   Community - Health Press Release
9th December 2009, 08:28pm - Views: 726






Culture International Roche 2 image








MEDIA RELEASE PR37494


Important Progress in Treatment of Early and Late Stage Breast Cancer With Herceptin, Avastin and T-

DM1


BASEL, Dec. 9 /PRNewswire-AsiaNet/ --


    - Roche to Present new Results That Could Offer a Better Future

to Women With Early and Very Advanced Breast Cancer, at the

CTRC-AACR San Antonio Breast Cancer Symposium

 

    Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new 5 year

follow-up data from two pivotal studies with Herceptin(R) (trastuzumab) in

early breast cancer; key results from a study of Avastin(R) (bevacizumab) in

the second-line treatment of advanced breast cancer and strong data on the

use of trastuzumab-DM1 (T-DM1), the first antibody-drug conjugate in

development for very advanced HER2-positive breast cancer, will all be

presented during the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS)

from 9 to 13 December 2009.


    "Breast cancer is the most common cancer among women worldwide with more

than one million new cases diagnosed every year and nearly 400,000 deaths, so

it is vital that we continue to provide more treatment options," said William

M. Burns, CEO of Roche Pharma. "The much anticipated data on Herceptin,

Avastin and the investigational drug T-DM1 will be welcomed by physicians

treating women with early and very advanced stages of breast cancer as it

will offer them more choices for fighting this devastating disease."


    Two Herceptin studies in early breast cancer, five year follow up data

(N9831, BCIRG 006)


    - 5-years of follow-up data will be presented from these pivotal phase

      III studies that have already shown efficacy in patients when adding 12

      months of Herceptin to standard therapy.


    - Both studies were seeking to answer questions the medical community has

     

been contemplating regarding the best way of giving their patients 

      Herceptin treatment.


Avastin RIBBON-2 study, second-line treatment data


    - Avastin is well established as a first-line treatment for women with

      advanced breast cancer. RIBBON-2 will report on the benefits of Avastin   

      in combination with commonly used chemotherapies in the second-line 

      setting where currently the only option is subsequent chemotherapy.


    T-DM1 4374 study in very advanced breast cancer


    New data from a phase II study (TDM4374) in a very advanced patient

population who have exhausted other treatment options will be presented. This

follows on from another phase II study (TDM4258) that was presented at ASCO

2009 which showed encouraging results in women with advanced HER2-positive

breast cancer.


    In addition, further data from the phase II study BO17929 will be

presented, demonstrating that the combination of pertuzumab and trastuzumab

shows efficacy in patients with HER2-positive advanced breast cancer whose

disease had progressed during prior treatment with Herceptin plus

chemotherapy.[i] The data, which suggest that combining pertuzumab and

trastuzumab may offer an effective new treatment option to patients with

HER2-positive advanced breast cancer, have been accepted as a poster

presentation on Saturday 12 Dec, 17:30 - 19:30, Poster Session 5, Exhibit

Halls A-B.


    Details of key studies being presented:


    Herceptin N9831 study


    The study is part of the official SABCS press programme on Saturday 12

Dec., 08:00 hrs.


    

    Dr E. Perez,   Results of chemotherapy alone, with        Oral

    et al          sequential or concurrent addition of       presentation

                   trastuzumab in the NCCTG N9831             Saturday 12

                   HER2-positive adjuvant breast cancer       Dec, 15:00,

                   trial.                                     General

                                                              Session 6,

                                                              Exhibit Hall

                                                              D.


    Herceptin BCIRG 006 study


    Dr. D. Slamon, Phase III randomized trial comparing       Oral

    et al          doxorubicin and cyclophosphamide followed  presentation

                   by docetaxel (AC à T) with doxorubicin and Saturday 12

                   cyclophosphamide followed by docetaxel and Dec, 09:45,

                   trastuzumab (AC à TH) with docetaxel,      General

                   carboplatin and trastuzumab (TCH) in       Session 5,

                   Her2neu positive early breast cancer       Exhibit Hall

                   patients: BCIRG 006 study.                 D.

    Avastin RIBBON-2 study


    The study is part of the official SABCS press programme on Friday 11

    Dec., 12:30 hrs.


    Dr. A.         RIBBON-2: A randomized, double-blind,      Oral

    Brufsky, et al placebo-controlled, phase III trial        presentation

                   evaluating the efficacy and safety of      Friday 11

                   bevacizumab in combination with            Dec, 15:00,

                   chemotherapy for second-line treatment of  General

                   HER2-negative metastatic breast cancer.    Session 4,

                                                              Exhibit Hall

                                                              D.

    T-DM1 4374 study


    Dr. I. Krop,   A phase II study of trastuzumab-DM1        Poster

    et al          (T-DM1), a novel HER2 antibody-drug        presentation

                   conjugate, in patients previously treated  Saturday 12

                   with lapatinib, trastuzumab, and           Dec, 07:00 -

                   chemotherapy.                              09:00.

                                                              Poster

                                                              Discussion

                                                              7, Ballroom

                                                              B.


    The above mentioned studies and data represent the latest

results of clinical research for each treatment and are not necessarily part

of the indicated licence in each country. For detailed label information,

visit the website of your health authority or the EMEA website


Culture International Roche 3 image


    In HER2-positive breast cancer, increased quantities of the HER2 protein

are present on the surface of the tumour cells. This is known as

'HER2-positivity'. High levels of HER2 are present in a particularly

aggressive form of the disease which responds poorly to chemotherapy.

Research shows that HER2-positivity affects approximately 20-30 percent of

women with breast cancer.[ii]


    The 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) takes

place from 9 to 13 December 2009. Full details can be found at



    About Roche


    Headquartered in Basel, Switzerland, Roche is a leader in

research-focused healthcare with combined strengths in pharmaceuticals and

diagnostics. Roche is the world's largest biotech company with truly

differentiated medicines in oncology, virology, inflammation, metabolism and

CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based

cancer diagnostics and a pioneer in diabetes management. Roche's personalised

healthcare strategy aims at providing medicines and diagnostic tools that

enable tangible improvements in the health, quality of life and survival of

patients.


    In 2008, Roche had over 80'000 employees worldwide and invested almost 9

billion Swiss francs in R&D.


    The Group posted sales of 45.6 billion Swiss francs. Genentech, United

States, is a wholly owned member of the Roche Group. Roche has a majority

stake in Chugai Pharmaceutical, Japan. For more information:



    All trademarks used or mentioned in this release are protected by law.


    Additional information


    - Roche SABCS materials:


    

    - More about Roche's work in oncology:


    

    - Oncology backgrounders:


    

    - Roche.com section on PHC:


    


    

    - Video clips and backgrounder on products:



    References


    [i] Baselga J. et al., Abstract 1004. American Society of Clinical

Oncology Annual Meeting 2007.


    [ii] Harries M, Smith I. The development and clinical use of trastuzumab

(Herceptin). Endocr Relat Cancer 9: 75-85, 2002.


    SOURCE: Roche


To view this and other AsiaNet releases please visit http://www.asianetnews.net






news articles logo NEWS ARTICLES
Contact News Articles |Remove this article